The latest research revealed that LPL/FABP4/CPT1, a fatty acid metabolism reprogramming axis, was significantly upregulated in nonalcoholic steatohepatitis (NASH) and cooperated with a large number of oncogenic signals to drive NASH to directly progress to hepatocellular carcinoma. The gene discussed is FABP4; the disease is metabolic dysfunction-associated steatohepatitis.